Stock performance snapshot and business context
PACS Group (PACS) has seen its share price under pressure recently, with a 3.5% decline over the past day, 4.6% over the past week, and double digit losses over the past month and past 3 months.
At a last close of US$33.44 and a market value of about US$5.3b, the company operates skilled nursing, assisted living, senior care, and independent living facilities across the United States. It generated US$5,288.9m in revenue and US$191.5m in net income.
See our latest analysis for PACS Group.
The recent 13.6% 1 month share price decline and 10.2% 3 month share price decline suggest momentum has cooled in the short term, even as the 1 year total shareholder return of about 180% remains very strong.
If this kind of swing in sentiment has you thinking about diversification, it could be a good moment to scan other opportunities using our screener of 36 healthcare AI stocks
With PACS Group shares under pressure after strong 1 year gains and trading below the average analyst price target, the key question is simple: is this weakness a buying opportunity or is future growth already priced in?
Most Popular Narrative: 4.5% Undervalued
At a last close of $33.44 versus a narrative fair value of $35.00, the most widely followed view sees modest upside supported by detailed long term assumptions.
The analysts have a consensus price target of $35.0 for PACS Group based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $32.0.
Curious what sits behind that fair value gap and the analyst spread? The narrative leans on rising earnings power, changing margins and a reset future P/E multiple. The exact mix of revenue growth, profitability and discounting might surprise you.
Result: Fair Value of $35 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative could be challenged if the integration of more than 100 acquired facilities drags on margins or if reimbursement policies in key states turn less supportive.
Find out about the key risks to this PACS Group narrative.
Another view: earnings multiple sends a different signal
The narrative fair value of $35.00 points to a modest 4.5% gap, but the current P/E of 27.4x is higher than the US Healthcare industry at 21.2x, the peer average at 22.0x, and the fair ratio of 20.7x. That richer multiple raises a simple question: is the story already baked into the price?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment split between recent share price weakness and a still-strong 1 year return, it helps to look at the full picture yourself and decide how comfortable you are with both the risks and rewards. Before you move on, take a moment to review the 3 key rewards
Looking for more investment ideas?
If PACS Group is on your radar, do not stop there. Use this moment to line up a few more ideas that fit your goals and risk comfort.
- Target resilience by checking out companies with strong finances and low leverage using the solid balance sheet and fundamentals stocks screener (39 results).
- Chase potential value by scanning companies that combine quality fundamentals with attractive pricing through the 54 high quality undervalued stocks.
- Hunt for off-the-radar potential by reviewing the screener containing 26 high quality undiscovered gems before the rest of the market catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com